Bulletin
Investor Alert

VBI Vaccines Inc.

NAS: VBIV

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jun 18, 2021, 7:59 p.m.

/zigman2/quotes/201705917/composite

$

3.87

Change

-0.05 -1.28%

Volume

Volume 710,039

Quotes are delayed by 20 min

/zigman2/quotes/201705917/composite

Previous close

$ 3.95

$ 3.92

Change

-0.03 -0.76%

Day low

Day high

$3.84

$4.12

Open

52 week low

52 week high

$2.07

$6.93

Open

Company Description

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like part...

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 and is headquartered in Cambridge, MA.

Valuation

Price to Sales Ratio

565.73

Price to Book Ratio

3.96

Enterprise Value to Sales

470.34

Total Debt to Enterprise Value

0.04

Efficiency

Revenue/Employee

8,354.00

Income Per Employee

-364,016.00

Receivables Turnover

0.26

Total Asset Turnover

0.01

Liquidity

Current Ratio

7.61

Quick Ratio

7.49

Cash Ratio

6.87

Profitability

Gross Margin

-919.79

Operating Margin

-4,110.93

Pretax Margin

-4,357.21

Net Margin

-4,357.21

Return on Assets

-27.89

Return on Equity

-35.57

Return on Total Capital

-29.66

Return on Invested Capital

-33.29

Capital Structure

Total Debt to Total Equity

10.42

Total Debt to Total Capital

9.44

Total Debt to Total Assets

8.55

Long-Term Debt to Equity

9.87

Long-Term Debt to Total Capital

8.94

Officers and Executives

Name Age Officer Since Title
Mr. Jeffrey R. Baxter 57 2016 President, Chief Executive Officer & Director
Mr. Christopher McNulty 42 2018 CFO & Head-Business Development
Dr. David Evander Anderson 50 2016 Chief Scientific Officer
Dr. Francisco Diaz-Mitoma 65 2016 Chief Medical Officer
Ms. Nell Beattie 32 2015 Director-Corporate Development & IR

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
06/09/2021 Perceptive Advisors LLC
320,388   Disposition at $4 per share. 1,281,552
06/09/2021 Perceptive Advisors LLC
1,102,179   Disposition at $4 per share. 4,408,716
06/09/2021 Perceptive Advisors LLC
465,936   1,281,324
06/09/2021 Perceptive Advisors LLC
1,602,888   4,407,942
04/24/2020 Perceptive Advisors LLC
9,090,909   Acquisition at $1.1 per share. 9,999,999
10/04/2019 Francisco Diaz-Mitoma
Chief Medical Officer
40,000   Acquisition at $0.5 per share. 20,000
09/30/2019 Jeffrey R. Baxter
CEO, President; Director
150,000   Acquisition at $0.5 per share. 75,000
09/30/2019 Francisco Diaz-Mitoma
Chief Medical Officer
14,500   Acquisition at $0.5 per share. 7,250
09/23/2019 Perceptive Advisors LLC
20,000,000   Acquisition at $0.5 per share. 10,000,000
06/27/2019 Francisco Diaz-Mitoma
Chief Medical Officer
8,000   Acquisition at $1.07 per share. 8,560
06/20/2019 Francisco Diaz-Mitoma
Chief Medical Officer
42,000   Acquisition at $0.89 per share. 37,380
06/20/2019 Francisco Diaz-Mitoma
Chief Medical Officer
10,000   Acquisition at $0.78 per share. 7,800
06/19/2019 Jeffrey R. Baxter
CEO, President; Director
144,000   Acquisition at $0.73 per share. 105,120
06/19/2019 Nell Beattie
Chief Business Officer
8,000   Acquisition at $0.74 per share. 5,920
06/17/2019 Perceptive Advisors LLC
1,000,000   Acquisition at $0.62 per share. 620,000
06/14/2019 Jeffrey R. Baxter
CEO, President; Director
31,250   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2019 David Evander Anderson
Chief Scientific Officer
21,875   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2019 Steven H. Gillis
Director
18,750   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2019 Nell Beattie
Chief Business Officer
6,250   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2019 Michel de Wilde
Director
12,500   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/vbiv

MarketWatch News on VBIV

  1. Novavax Inc. stock falls Friday, underperforms market

    5:12 p.m. June 18, 2021

    - MarketWatch Automation

  2. Novavax Inc. stock outperforms market on strong trading day

    5:13 p.m. June 17, 2021

    - MarketWatch Automation

  3. Novavax Inc. stock underperforms Wednesday when compared to competitors

    5:13 p.m. June 16, 2021

    - MarketWatch Automation

  4. Novavax Inc. stock falls Tuesday, underperforms market

    5:13 p.m. June 15, 2021

    - MarketWatch Automation

  5. Novavax Inc. stock falls Monday, underperforms market

    5:13 p.m. June 14, 2021

    - MarketWatch Automation

  6. Novavax Inc. stock underperforms Thursday when compared to competitors

    5:13 p.m. June 10, 2021

    - MarketWatch Automation

  7. Novavax Inc. stock rises Wednesday, outperforms market

    5:13 p.m. June 9, 2021

    - MarketWatch Automation

  8. Novavax Inc. stock outperforms market on strong trading day

    5:12 p.m. June 8, 2021

    - MarketWatch Automation

  9. Novavax Inc. stock outperforms competitors on strong trading day

    5:13 p.m. June 7, 2021

    - MarketWatch Automation

  10. Novavax Inc. stock outperforms market on strong trading day

    5:13 p.m. June 4, 2021

    - MarketWatch Automation

  11. Novavax Inc. stock outperforms market on strong trading day

    5:13 p.m. June 3, 2021

    - MarketWatch Automation

  12. Novavax Inc. stock outperforms market on strong trading day

    5:13 p.m. June 2, 2021

    - MarketWatch Automation

  13. Novavax Inc. stock falls Tuesday, underperforms market

    5:13 p.m. June 1, 2021

    - MarketWatch Automation

  14. Novavax Inc. stock falls Friday, underperforms market

    5:13 p.m. May 28, 2021

    - MarketWatch Automation

  15. Novavax Inc. stock underperforms Thursday when compared to competitors

    5:13 p.m. May 27, 2021

    - MarketWatch Automation

  16. Novavax Inc. stock outperforms market on strong trading day

    5:13 p.m. May 26, 2021

    - MarketWatch Automation

  17. Novavax Inc. stock outperforms market on strong trading day

    5:13 p.m. May 25, 2021

    - MarketWatch Automation

  18. Novavax Inc. stock outperforms market on strong trading day

    5:13 p.m. May 24, 2021

    - MarketWatch Automation

  19. Novavax Inc. stock underperforms Friday when compared to competitors

    5:14 p.m. May 21, 2021

    - MarketWatch Automation

  20. Loading more headlines...
/news/nonmarketwatch/company/us/vbiv

Other News on VBIV

  1. Will coronavirus eventually become like the seasonal flu?

    9:19 a.m. Today

    - Seeking Alpha

  2. Why Agenus Stock Is Jumping Today

    11:45 a.m. June 8, 2021

    - Motley Fool

  3. WKHS, BNGO, CLOV and SFIX among notable premarket gainers

    8:26 a.m. June 8, 2021

    - Seeking Alpha

  4. VBI Vaccines (VBIV) Receives a Buy from BMO Capital

    10:06 a.m. May 11, 2021

    - SmarterAnalyst

  5. VBI Vaccines (VBIV) Gets a Buy Rating from Raymond James

    7:26 a.m. May 11, 2021

    - SmarterAnalyst

  6. VBI Vaccines (VBIV) Gets a Buy Rating from Oppenheimer

    4:25 a.m. May 11, 2021

    - SmarterAnalyst

  7. 10-Q: VBI VACCINES INC/BC

    8:03 a.m. May 10, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  8. VBI Vaccines reports preclinical VBI-2902 data in COVID-19

    8:38 a.m. April 28, 2021

    - Seeking Alpha

  9. Dynavax (DVAX) Up on Positive COVID-19 Vaccine Study Data

    9:34 a.m. April 7, 2021

    - Zacks.com

  10. Loading more headlines...

At a Glance

VBI Vaccines, Inc.

222 3rd Street

Suite 2241

Cambridge, Massachusetts 02142

Phone

1 6178303031

Industry

-

Sector

-

Fiscal Year-end

12/2021

Revenue

$1.06M

Net Income

$-46.23M

Employees

127.00

/news/pressrelease/company/us/vbiv

Press Releases on VBIV

  1. VBI Vaccines to Present at Upcoming Scientific Conferences

    8:00 a.m. June 17, 2021

    - BusinessWire - BZX

  2. VBI Vaccines Announces Results of Annual General Meeting

    6:18 p.m. June 9, 2021

    - BusinessWire - BZX

  3. Canadian Biotech Industry Ready to Wave the Flag at BIO Digital

    1:27 p.m. June 8, 2021

    - BusinessWire - BZX

  4. VBI Vaccines to Participate in Upcoming Investor Conferences

    8:00 a.m. June 1, 2021

    - BusinessWire - BZX

  5. Loading more headlines...
Link to MarketWatch's Slice.